Sacubitril/valsartan in the treatment of arterial hypertension: An unaccomplished promise?

Abstract

Arterial hypertension continues to be the leading cause of death worldwide and, unfortunately, remains uncontrolled in a significant percentage of hypertensive patients who do not attain the blood pressure (BP) goal that most guidelines recommend (<140/90 mm Hg). A lively debate began after the publication of the Systolic Blood Pressure Intervention Trial (SPRINT), in which a goal of 120 mm Hg was reported to be adequate in a portion of the hypertensive population.